We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Kala Pharmaceuticals

News List

Kala Pharmaceuticals announces FDA approval of EYSUVIS for short-term treatment of dry eye disease pharmaceutical-business-review
October 30, 2020
Kala Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease.
Kala’s dry eye disease candidate KPI-121 meets objective in STRIDE 3 trial pharmaceutical-business-review
March 12, 2020
Kala Pharmaceuticals said that its dry eye disease candidate KPI-121 0.25% has delivered positive results in a phase 3 trial called STRIDE 3.
FDA Accepts New Drug Application for KPI-121 0.25% americanpharmaceuticalreview
December 29, 2018
Kala Pharmaceuticals announced the New Drug Application (NDA) for KPI-121 0.25%, a product candidate for the temporary relief of signs and symptoms of dry eye disease utilizing......